FDA grants orphan drug designation to OBI-999 for gastric cancer

The FDA granted orphan drug designation to the antibody-drug conjugate OBI-999 for the treatment of gastric cancer, according to the agent’s manufacturer.OBI-999 (OBI Pharma) targets Globo H, a glycolipid antigen expressed in up to 15 epithelial cancers.Enrollment is underway for a phase 1/phase 2 trial designed to evaluate the safety and efficacy of OBI-999 for patients with locally advanced or metastatic solid tumors, including gastric, pancreatic, esophageal and colorectal cancers. Apostolia M. Tsimberidou, MD, PhD, tenured professor in the department of investigational cancerRead More

Share on facebook
Share on twitter
Share on linkedin